Ardelyx Prepares for Battle with FDA Over Rejected CKD Drug

Ardelyx, Inc. is lacing up the gloves and preparing to wade into the ring with the U.S. Food and Drug Administration (FDA) to dispute the July rejection of its chronic kidney disease drug, tenapanor.